Answers are grounded in this paper and cite their sources.
Bladder cancer is the most expensive malignancy to treat over the lifetime of patients What is not often recognized, particularly by treating physicians, is that these costs are frequently a source of great concern and anxiety among patients with the disease and their families -a condition termed "financial toxicity" (FT). This was emphasized in a recent article by a team at the University of North Carolina's Lineberger Comprehensive Cancer Center In it, researchers identified patients with a diagnosis of bladder cancer from Cancer Center rosters and asked them to reply via a computer assisted telephone survey to questions about demographics, healthcare access, comorbid conditions and treatments for those conditions and their bladder cancer. Additional questions came from validated questionnaires on FT and health related quality-of-life (HRQOL).
No takes yet. Share an insight, caveat, or question.
Edward M. Messing (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: